Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-08-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: smallhepatitiscelllung cancerevidence of
  Phrases that lowered it: influenzavaccinehas receivedthe effecteffect of
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 26.5% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past termination rate: 7.6% (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 7327 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC NCT03689855 · started 2019 · scored riskier than 81% of active trials completed
• Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma NCT03502746 · started 2018 · scored riskier than 78% of active trials terminated
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: NCT02348008 · started 2015 · scored riskier than 93% of active trials completed
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) NCT03971474 · started 2019 · scored riskier than 72% of active trials completed
• Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy NCT03904108 · started 2019 · scored riskier than 88% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.